Cargando…
Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?
Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139355/ https://www.ncbi.nlm.nih.gov/pubmed/32182949 http://dx.doi.org/10.3390/cancers12030635 |
_version_ | 1783518746865827840 |
---|---|
author | Goineau, Aurore Campion, Loïc Commer, Jean-Marie Vié, Brigitte Ghesquière, Agnès Béra, Guillaume Jaffres, Didier Magné, Nicolas Artignan, Xavier Chamois, Jérôme Bergerot, Philippe Créhange, Gilles Deniaud-Alexandre, Elisabeth Buthaud, Xavier Belkacémi, Yazid Doré, Mélanie De Decker, Laure Supiot, Stéphane |
author_facet | Goineau, Aurore Campion, Loïc Commer, Jean-Marie Vié, Brigitte Ghesquière, Agnès Béra, Guillaume Jaffres, Didier Magné, Nicolas Artignan, Xavier Chamois, Jérôme Bergerot, Philippe Créhange, Gilles Deniaud-Alexandre, Elisabeth Buthaud, Xavier Belkacémi, Yazid Doré, Mélanie De Decker, Laure Supiot, Stéphane |
author_sort | Goineau, Aurore |
collection | PubMed |
description | Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged 75 years or older treated with curative intent radiotherapy with or without androgen deprivation therapy (ADT) for localized prostate cancer. We prospectively performed comprehensive geriatric assessment (CGA) and administered QoL questionnaires to 208 elderly (>75 years) patients prior to, plus two and six months after, radiotherapy (NCT 02876237). The median age of the patients was 77 years (range 75–89). At the start of the study, comorbidities were highlighted in 65% of patients: 23% were depressed, 23% had cognitive impairment, and 16% had reduced independence. At six months, 9% of patients had a consistently decreased QoL (>20 points), and a further 16% had a more moderate reduction (10 to 20 points) in QoL. None of the parameters studied (tumor characteristic, treatment, or oncogeriatric parameters) were predictive of a reduced QoL following radiotherapy. Though co-existing geriatric impairment was common, QoL was maintained for 75% of patients six months after radiotherapy. CGA was poorly predictive of tolerance of prostatic radiotherapy. Geriatric assessments dedicated to quality of life following radiotherapy need to be developed. |
format | Online Article Text |
id | pubmed-7139355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71393552020-04-10 Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? Goineau, Aurore Campion, Loïc Commer, Jean-Marie Vié, Brigitte Ghesquière, Agnès Béra, Guillaume Jaffres, Didier Magné, Nicolas Artignan, Xavier Chamois, Jérôme Bergerot, Philippe Créhange, Gilles Deniaud-Alexandre, Elisabeth Buthaud, Xavier Belkacémi, Yazid Doré, Mélanie De Decker, Laure Supiot, Stéphane Cancers (Basel) Article Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged 75 years or older treated with curative intent radiotherapy with or without androgen deprivation therapy (ADT) for localized prostate cancer. We prospectively performed comprehensive geriatric assessment (CGA) and administered QoL questionnaires to 208 elderly (>75 years) patients prior to, plus two and six months after, radiotherapy (NCT 02876237). The median age of the patients was 77 years (range 75–89). At the start of the study, comorbidities were highlighted in 65% of patients: 23% were depressed, 23% had cognitive impairment, and 16% had reduced independence. At six months, 9% of patients had a consistently decreased QoL (>20 points), and a further 16% had a more moderate reduction (10 to 20 points) in QoL. None of the parameters studied (tumor characteristic, treatment, or oncogeriatric parameters) were predictive of a reduced QoL following radiotherapy. Though co-existing geriatric impairment was common, QoL was maintained for 75% of patients six months after radiotherapy. CGA was poorly predictive of tolerance of prostatic radiotherapy. Geriatric assessments dedicated to quality of life following radiotherapy need to be developed. MDPI 2020-03-09 /pmc/articles/PMC7139355/ /pubmed/32182949 http://dx.doi.org/10.3390/cancers12030635 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Goineau, Aurore Campion, Loïc Commer, Jean-Marie Vié, Brigitte Ghesquière, Agnès Béra, Guillaume Jaffres, Didier Magné, Nicolas Artignan, Xavier Chamois, Jérôme Bergerot, Philippe Créhange, Gilles Deniaud-Alexandre, Elisabeth Buthaud, Xavier Belkacémi, Yazid Doré, Mélanie De Decker, Laure Supiot, Stéphane Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? |
title | Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? |
title_full | Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? |
title_fullStr | Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? |
title_full_unstemmed | Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? |
title_short | Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? |
title_sort | can comprehensive geriatric assessment predict tolerance of radiotherapy for localized prostate cancer in men aged 75 years or older? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139355/ https://www.ncbi.nlm.nih.gov/pubmed/32182949 http://dx.doi.org/10.3390/cancers12030635 |
work_keys_str_mv | AT goineauaurore cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT campionloic cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT commerjeanmarie cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT viebrigitte cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT ghesquiereagnes cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT beraguillaume cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT jaffresdidier cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT magnenicolas cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT artignanxavier cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT chamoisjerome cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT bergerotphilippe cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT crehangegilles cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT deniaudalexandreelisabeth cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT buthaudxavier cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT belkacemiyazid cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT doremelanie cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT dedeckerlaure cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder AT supiotstephane cancomprehensivegeriatricassessmentpredicttoleranceofradiotherapyforlocalizedprostatecancerinmenaged75yearsorolder |